Bioventus (NASDAQ:BVS) Reaches New 1-Year High – Here’s What Happened

Bioventus Inc. (NASDAQ:BVS)’s stock price reached a new 52-week high during trading on Tuesday . The company traded as high as $12.99 and last traded at $12.9250, with a volume of 57111 shares changing hands. The stock had previously closed at $12.45.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on BVS. Canaccord Genuity Group restated a “buy” rating and issued a $15.00 price objective on shares of Bioventus in a report on Tuesday, June 16th. Weiss Ratings reiterated a “hold (c)” rating on shares of Bioventus in a research note on Tuesday, June 2nd. Finally, Barrington Research reissued an “outperform” rating and issued a $14.00 target price on shares of Bioventus in a report on Tuesday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Bioventus has a consensus rating of “Buy” and an average target price of $14.75.

Bioventus Stock Down 0.7%

The company’s 50-day moving average price is $10.14 and its 200 day moving average price is $9.41. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.13 and a current ratio of 1.69. The stock has a market cap of $1.10 billion, a PE ratio of 32.00, a price-to-earnings-growth ratio of 1.68 and a beta of 0.65.

Bioventus (NASDAQ:BVS) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.06. The company had revenue of $132.09 million for the quarter. Bioventus had a net margin of 4.94% and a return on equity of 29.97%. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. As a group, analysts forecast that Bioventus Inc. will post 0.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Bioventus by 7.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock worth $211,000 after purchasing an additional 1,538 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Bioventus by 19.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 162,412 shares of the company’s stock worth $1,486,000 after purchasing an additional 26,103 shares during the period. Legal & General Group Plc lifted its position in Bioventus by 100.9% during the second quarter. Legal & General Group Plc now owns 71,409 shares of the company’s stock valued at $473,000 after purchasing an additional 35,873 shares in the last quarter. Rhumbline Advisers lifted its position in Bioventus by 20.6% during the second quarter. Rhumbline Advisers now owns 65,093 shares of the company’s stock valued at $431,000 after purchasing an additional 11,133 shares in the last quarter. Finally, Marshall Wace LLP grew its holdings in Bioventus by 32.5% during the second quarter. Marshall Wace LLP now owns 211,695 shares of the company’s stock valued at $1,401,000 after purchasing an additional 51,951 shares during the period. Hedge funds and other institutional investors own 62.94% of the company’s stock.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non?surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low?intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.